Newsfeeds - Spark Newswire

2 minute read

Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday

Today, 5:33 PM

Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close at $114.92 on Friday.

AAPL

1 minute read

SVB Leerink Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $315

By Benzinga Newsdesk

Today, 5:33 PM

SVB Leerink analyst Mike Kratky maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and raises the price target from $145 to $315.

MDGL

2 minute read

Tesla, Amazon, Apple, Madrigal, Walt Disney: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair

Today, 5:33 PM

Major Wall Street indices closed in the red on Monday as investor optimism on the much-anticipated Santa Claus rally began to fade over fears of recession gaining momentum.

AAPL

5 minute read

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 5:33 PM

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

ACLX

1 minute read

Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday

By Lisa Levin

Today, 5:33 PM

U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.

AMRS

1 minute read

STAT News Reporter Adam Feuerstein Tweets “Intercept Pharmaceuticals Down 10% Because OCA’s Future In NASH Looks Bleaker. Investors Really Want Intercept To Ditch NASH And Focus On The Approved PBC Indication”

By Benzinga Newsdesk

Today, 5:33 PM

https://twitter.com/adamfeuerstein/status/1604856612514037761

ICPT

2 minute read

Madrigal Announced Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis; Potentially Clinically Meaningful LDL-lowering, a Key Secondary Endpoint

By Charles Gross

Today, 5:33 PM

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides an overview of upcoming resmetirom Phase 3 data presentations and reports third quarter 2022 financial results.

MDGL

2 minute read

Tesla, Amazon, Madrigal Pharma, Pfizer, Synaptogenix: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair

Today, 5:33 PM

Major Wall Street indices had closed in the red on Friday in the wake of a continued sell-off following the hawkish stance asserted by the Federal Reserve. Friday witnessed volatile trading as a large number of o

AMZN

4 minute read

Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

Today, 5:33 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

BIIB

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For July 8, 2022

By Benzinga Insights

Today, 5:33 PM